WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024.
Read more at globenewswire.comXilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
XILIO THERAPEUTICS INC
NASDAQ:XLO (2/12/2025, 8:00:03 PM)
After market: 1.3501 -0.13 (-8.78%)1.48
+0.82 (+125.27%)
XLO Latest News and Analysis
8 hours ago - ChartmillKeep an eye on the top gainers and losers in Wednesday's session.Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
9 hours ago - ChartmillThese stocks are the most active in today's sessionLet's have a look at what is happening on the US markets on Wednesday. Below you can find the most active stocks in today's session.
10 hours ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
12 hours ago - ChartmillTraders are paying attention to the gapping stocks in Wednesday's session.The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
